COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.

Dernoncourt A, Schmidt J, Duhaut P, Liabeuf S, Gras-Champel V, Masmoudi K, Bennis Y, Batteux B

Open source

DOI
10.1111/fcp.12695
Published
2022 Feb
Container
Fundamental & clinical pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/fcp.12695,
  title = {COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.},
  author = {Dernoncourt A and Schmidt J and Duhaut P and Liabeuf S and Gras-Champel V and Masmoudi K and Bennis Y and Batteux B},
  year = {2022},
  journal = {Fundamental \& clinical pharmacology},
  doi = {10.1111/fcp.12695},
  url = {https://doi.org/10.1111/fcp.12695}
}

RIS

TY  - JOUR
TI  - COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.
AU  - Dernoncourt A
AU  - Schmidt J
AU  - Duhaut P
AU  - Liabeuf S
AU  - Gras-Champel V
AU  - Masmoudi K
AU  - Bennis Y
AU  - Batteux B
PY  - 2022
JO  - Fundamental & clinical pharmacology
DO  - 10.1111/fcp.12695
UR  - https://doi.org/10.1111/fcp.12695
ER  - 

APA

A, D., J, S., P, D., S, L., V, G., K, M., Y, B., & B, B. (2022). COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.. Fundamental & clinical pharmacology. https://doi.org/10.1111/fcp.12695

Source records